001438586 000__ 06524cam\a2200625\a\4500
001438586 001__ 1438586
001438586 003__ OCoLC
001438586 005__ 20230309004313.0
001438586 006__ m\\\\\o\\d\\\\\\\\
001438586 007__ cr\un\nnnunnun
001438586 008__ 210731s2021\\\\sz\\\\\\o\\\\\001\0\eng\d
001438586 019__ $$a1261878754$$a1268574233$$a1284943881
001438586 020__ $$a9783030734404$$q(electronic bk.)
001438586 020__ $$a3030734404$$q(electronic bk.)
001438586 020__ $$z9783030734398
001438586 0247_ $$a10.1007/978-3-030-73440-4$$2doi
001438586 035__ $$aSP(OCoLC)1262374382
001438586 040__ $$aEBLCP$$beng$$epn$$cEBLCP$$dYDX$$dGW5XE$$dOCLCO$$dEBLCP$$dOCLCF$$dUKAHL$$dDKU$$dOCLCQ$$dCOM$$dOCLCO$$dN$T$$dOCLCQ
001438586 049__ $$aISEA
001438586 050_4 $$aRC280.B6
001438586 08204 $$a616.99/418$$223
001438586 24500 $$aResistance to targeted therapies in multiple myeloma /$$cSilvia CW Ling, Steven Trieu, editors.
001438586 260__ $$aCham :$$bSpringer,$$c2021.
001438586 300__ $$a1 online resource (161 pages)
001438586 336__ $$atext$$btxt$$2rdacontent
001438586 337__ $$acomputer$$bc$$2rdamedia
001438586 338__ $$aonline resource$$bcr$$2rdacarrier
001438586 347__ $$atext file
001438586 347__ $$bPDF
001438586 4901_ $$aResistance to targeted anti-cancer therapeutics ;$$vv. 22
001438586 500__ $$a4.5.6 The Bone Marrow Microenvironment.
001438586 500__ $$aIncludes index.
001438586 5050_ $$aIntro -- Aims and Scope -- Objective -- Preface -- Contents -- Series Editor Biography -- About the Series Editor -- Contributors -- About the Editors -- Chapter 1: The Role of Targeted Therapy in Multiple Myeloma -- 1.1 Multiple Myeloma Overview -- 1.2 Historical Treatment of Multiple Myeloma Until Present -- 1.3 Immunomodulatory Imide Drugs -- 1.4 Proteasome Inhibitors -- 1.5 Monoclonal Antibodies -- 1.6 Histone Deacetylase Inhibitors -- 1.7 Bone Targeted Therapy -- 1.8 New Agents on the Horizon -- 1.9 Conclusion -- References -- Chapter 2: Lenalidomide -- 2.1 Introduction
001438586 5058_ $$a2.2 Indications -- 2.3 Efficacy of Lenalidomide -- 2.3.1 Efficacy in Relapsed or Refractory Multiple Myeloma -- 2.3.1.1 Lenalidomide and Dexamethasone -- 2.3.1.2 Bortezomib, Lenalidomide, and Dexamethasone -- 2.3.1.3 Daratumumab, Lenalidomide, and Dexamethasone -- 2.3.1.4 Carfilzomib, Lenalidomide, and Dexamethasone -- 2.3.2 Efficacy in Newly Diagnosed Multiple Myeloma -- 2.3.2.1 Transplant Ineligible Patients -- Lenalidomide and Dexamethasone -- Cyclophosphamide, Lenalidomide, and Dexamethasone -- Bortezomib, Lenalidomide, and Dexamethasone -- 2.3.2.2 Transplant Eligible Patients
001438586 5058_ $$aBortezomib, Lenalidomide, and Dexamethasone -- 2.4 Mechanisms of Action -- 2.4.1 Cereblon Pathway -- 2.4.2 Effect on Cytokines -- 2.4.3 T Cell Activation -- 2.4.4 Effect on Natural Killer Cells -- 2.4.5 Anti-Angiogenic Activity -- 2.4.6 Direct Antitumor Activity -- 2.4.7 Myeloma Microenvironment -- 2.5 Lenalidomide Resistance -- 2.5.1 Potential Mechanisms of Lenalidomide Resistance -- 2.5.1.1 Decreased Cereblon Expression and Downstream Factors -- 2.5.1.2 Increase in c-Myc -- 2.5.2 Management of Lenalidomide-Resistant Disease -- 2.5.2.1 Pomalidomide-Based Regimes
001438586 5058_ $$a2.5.2.2 Proteasome Inhibitor and Daratumumab-Based Regimes -- 2.6 Conclusion -- References -- Chapter 3: Pomalidomide -- 3.1 Introduction -- 3.2 Clinical Indication of Pomalidomide -- 3.3 Efficacy -- 3.3.1 Efficacy in Relapsed and Refractory Multiple Myeloma -- 3.3.1.1 Pomalidomide and Dexamethasone -- 3.3.1.2 Pomalidomide + Dexamethasone + Cyclophosphamide -- 3.3.1.3 Pomalidomide, Bortezomib, and Dexamethasone -- 3.3.1.4 Pomalidomide, Daratumumab, and Dexamethasone -- 3.3.1.5 Pembrolizumab, Pomalidomide, and Dexamethasone -- 3.4 Mechanisms of Pomalidomide Action
001438586 5058_ $$a3.5 Potential Mechanism of Pomalidomide Resistance and Overcoming Resistance -- 3.6 Conclusion -- References -- Chapter 4: Mechanisms Driving Resistance to Proteasome Inhibitors Bortezomib, Carfilzomib, and Ixazomib in Multiple Myeloma -- 4.1 Introduction -- 4.2 The Proteasome -- 4.3 Endoplasmic Reticulum Stress -- 4.4 Proteasome Inhibitors in Multiple Myeloma -- 4.5 Bortezomib Resistance Mechanisms -- 4.5.1 Proteasome Mutation and Overexpression -- 4.5.2 Drug Efflux -- 4.5.3 Plasma Cell Differentiation -- 4.5.4 Upregulation of Heat Shock Proteins -- 4.5.5 Autophagy
001438586 506__ $$aAccess limited to authorized users.
001438586 520__ $$aMultiple Myeloma remains an incurable malignancy. As the disease progresses, it invariably becomes resistant to treatment and almost all patients develop refractory disease. There are multiple different types of targeted therapies and many of them are used in combination at different stages of disease. Targeted therapies that are approved to be used include Proteasome Inhibitors, Immunomodulatory Drugs and Monoclonal Antibodies. Second and third generations of these drugs are developed to overcome resistance and they have unique mechanism of actions. Targeted therapies that are undergoing clinical trials include CAR-T cells, bi-specific antibodies, vaccines, ubiquitin ligase inhibitors and BCL-2 inhibitors. This book will help to develop an understanding of targeted therapies in Multiple Myeloma. Its goal is to provide a unique review of the mechanism of action and resistance of the many targeted therapies in Multiple Myeloma by leaders of the field. The book will be useful for students in medical science, clinicians, health professionals, scientists, pharmaceutical professionals, drug developers, and policy makers. This book will provide an insightful knowledge of the biology of Multiple Myeloma, the mechanism of action and resistance of targeted therapies, application of biomarkers and genomics and possible strategies in overcoming resistance and future development.
001438586 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed August 2, 2021).
001438586 650_0 $$aDrug resistance in cancer cells.
001438586 650_0 $$aMultiple myeloma$$xTreatment.
001438586 650_6 $$aCellules cancéreuses$$xRésistance aux médicaments.
001438586 650_6 $$aMyélome multiple$$xTraitement.
001438586 655_0 $$aElectronic books.
001438586 7001_ $$aLing, Silvia Cw.
001438586 7001_ $$aTrieu, Steven.
001438586 77608 $$iPrint version:$$aLing, Silvia Cw.$$tResistance to Targeted Therapies in Multiple Myeloma.$$dCham : Springer International Publishing AG, ©2021$$z9783030734398
001438586 830_0 $$aResistance to targeted anti-cancer therapeutics ;$$vv. 22.
001438586 852__ $$bebk
001438586 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-73440-4$$zOnline Access$$91397441.1
001438586 909CO $$ooai:library.usi.edu:1438586$$pGLOBAL_SET
001438586 980__ $$aBIB
001438586 980__ $$aEBOOK
001438586 982__ $$aEbook
001438586 983__ $$aOnline
001438586 994__ $$a92$$bISE